GYRE THERAPEUTICS INC (GYRE) competitors & alternatives
Health Care · NASDAQ
GYRE THERAPEUTICS INC (GYRE)'s top competitors and alternatives — its most similar public companies — include CONTINEUM THERAPEUTICS INC CLASS A (CTNM), SAGIMET BIOSCIENCES INC SERIES A (SGMT), GALECTIN THERAPEUTICS INC (GALT), SIONNA THERAPEUTICS INC (SION), MADRIGAL PHARMACEUTICALS, INC. (MDGL), Vertex Pharmaceuticals (VRTX), ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT), LIQUIDIA CORP (LQDA), ARMATA PHARMACEUTICALS INC (ARMP), SAVARA INC (SVRA), Insmed (INSM) and TREVI THERAPEUTICS INC (TRVI). These are GYRE THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GYRE competitors & alternatives
-
CONTINEUM THERAPEUTICS INC CLASS ACTNMHealth Care
A clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroimmune and inflammatory indications, with lead programs PIPE-791…
$14.73 (as of 2026-07-22) · market cap $518M
-
SAGIMET BIOSCIENCES INC SERIES ASGMTHealth Care
Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other…
$7.05 (as of 2026-07-22) · market cap $431M
-
GALECTIN THERAPEUTICS INCGALTHealth Care
Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer.
$3.50 (as of 2026-07-22) · market cap $253M
-
SIONNA THERAPEUTICS INCSIONHealth Care
A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
$45.03 (as of 2026-07-22) · market cap $2.1B
-
MADRIGAL PHARMACEUTICALS, INC.MDGLHealth Care
Madrigal is a commercial-stage biotech company exclusively focused on Rezdiffra, the first FDA-approved treatment for MASH with moderate-to-advanced fibrosis,…
$537.65 (as of 2026-07-22) · market cap $12.4B
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$472.57 (as of 2026-07-22) · market cap $121.4B
-
ARCTURUS THERAPEUTICS HOLDINGS INCARCTHealth Care
Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue…
$5.93 (as of 2026-07-22) · market cap $168M
-
LIQUIDIA CORPLQDAHealth Care
Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering,…
$87.04 (as of 2026-07-22) · market cap $7.7B
-
ARMATA PHARMACEUTICALS INCARMPHealth Care
Armata is a clinical-stage phage biotech using engineered bacteriophages as a targeted, microbiome-friendly alternative to antibiotics for drug-resistant…
$5.24 (as of 2026-07-22) · market cap $194M
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
Not quite? Describe exactly what you want →
Peers are GYRE THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: GYRE THERAPEUTICS INC (GYRE).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.